At EG427 our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes to address prevalent diseases in neurology. Our lead asset EG110A, for the treatment of neurogenic bladder dysfunction, has received IND clearance in June 2024 from the US FDA. Our revolutionary approach to the treatment of this disease aims at providing patients with a comprehensive, long-term solution to their bladder management, through a highly selective molecular biology approach overcoming the drawbacks of current standard of care. Our HQ and labs are in Paris, France, where we were founded in 2019. We have raised over USD 21 million, including from our Series A in 2021. " title="" class="btn" data-container="body" data-html="true" data-id="208011" data-placement="top" data-toggle="popover" data-trigger="focus" style="color:#0077b5" tabindex="0" data-original-title="EG 427 "> 1,612
Activities
Technologies
Entity types
Location
29 Rue du Faubourg Saint-Jacques, 75014 Paris, France
Paris
France
Employees
Scale: 11-50
Estimated: 24
Engaged corporates
2Added in Motherbase
1 year, 6 months agoPinpoint Gene Therapy
At EG427 our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes to address prevalent diseases in neurology.
Our lead asset EG110A, for the treatment of neurogenic bladder dysfunction, has received IND clearance in June 2024 from the US FDA. Our revolutionary approach to the treatment of this disease aims at providing patients with a comprehensive, long-term solution to their bladder management, through a highly selective molecular biology approach overcoming the drawbacks of current standard of care.
Our HQ and labs are in Paris, France, where we were founded in 2019. We have raised over USD 21 million, including from our Series A in 2021.
Gene therapy, peripheral nervous system disorders, neurogenic bladder, HSV-1 vector platform, urinary bladder dysfunction, Herpes type 1 gene therapy platform, and treatment of nervous system disorders
Pinpoint Gene Therapy
At EG427 our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes to address prevalent diseases in neurology.
Our lead asset EG110A, for the treatment of neurogenic bladder dysfunction, has received IND clearance in June 2024 from the US FDA. Our revolutionary approach to the treatment of this disease aims at providing patients with a comprehensive, long-term solution to their bladder management, through a highly selective molecular biology approach overcoming the drawbacks of current standard of care.
Our HQ and labs are in Paris, France, where we were founded in 2019. We have raised over USD 21 million, including from our Series A in 2021.
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
![]() Paris Biotech Santé Startup accelerator & VC, Civic and Social Organizations | Paris Biotech Santé Startup accelerator & VC, Civic and Social Organizations | Other 20 Oct 2023 | | |
![]() SATT Paris-Saclay Research, Startup accelerator & VC, Research Services | SATT Paris-Saclay Research, Startup accelerator & VC, Research Services | Other 30 Sep 2024 | |